Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.

Brizzi A, Cascio MG, Frosini M, Ligresti A, Aiello F, Biotti I, Brizzi V, Pertwee RG, Corelli F, Di Marzo V.

J Med Chem. 2011 Dec 22;54(24):8278-88. doi: 10.1021/jm200529h. Epub 2011 Nov 16.

PMID:
22044209
2.

New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo.

Brizzi A, Brizzi V, Cascio MG, Corelli F, Guida F, Ligresti A, Maione S, Martinelli A, Pasquini S, Tuccinardi T, Di Marzo V.

J Med Chem. 2009 Apr 23;52(8):2506-14. doi: 10.1021/jm8016255.

PMID:
19331413
3.

The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.

Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL.

J Pharmacol Exp Ther. 2005 Aug;314(2):868-75. Epub 2005 May 18.

PMID:
15901805
4.

Synthesis and CB1 receptor activities of dimethylheptyl derivatives of 2-arachidonoyl glycerol (2-AG) and 2-arachidonyl glyceryl ether (2-AGE).

Parkkari T, Salo OM, Huttunen KM, Savinainen JR, Laitinen JT, Poso A, Nevalainen T, Järvinen T.

Bioorg Med Chem. 2006 Apr 15;14(8):2850-8. Epub 2006 Jan 5.

PMID:
16403642
5.

Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.

Brizzi A, Aiello F, Marini P, Cascio MG, Corelli F, Brizzi V, De Petrocellis L, Ligresti A, Luongo L, Lamponi S, Maione S, Pertwee RG, Di Marzo V.

Bioorg Med Chem. 2014 Sep 1;22(17):4770-83. doi: 10.1016/j.bmc.2014.07.006. Epub 2014 Jul 12.

PMID:
25065940
6.

Development of endocannabinoid-based chemical probes for the study of cannabinoid receptors.

Martín-Couce L, Martín-Fontecha M, Capolicchio S, López-Rodríguez ML, Ortega-Gutiérrez S.

J Med Chem. 2011 Jul 28;54(14):5265-9. doi: 10.1021/jm2004392. Epub 2011 Jun 27.

PMID:
21675776
7.

Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.

van der Stelt M, van Kuik JA, Bari M, van Zadelhoff G, Leeflang BR, Veldink GA, Finazzi-Agrò A, Vliegenthart JF, Maccarrone M.

J Med Chem. 2002 Aug 15;45(17):3709-20.

PMID:
12166944
8.

Alpha-methylated derivatives of 2-arachidonoyl glycerol: synthesis, CB1 receptor activity, and enzymatic stability.

Parkkari T, Myllymäki M, Savinainen JR, Saario SM, Castillo-Meléndez JA, Laitinen JT, Nevalainen T, Koskinen AM, Järvinen T.

Bioorg Med Chem Lett. 2006 May 1;16(9):2437-40. Epub 2006 Feb 8.

PMID:
16466915
9.

Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2.

Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE.

Mol Pharmacol. 2006 Jul;70(1):101-11. Epub 2006 Apr 12.

PMID:
16611855
10.

Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.

Suhara Y, Oka S, Kittaka A, Takayama H, Waku K, Sugiura T.

Bioorg Med Chem. 2007 Jan 15;15(2):854-67. Epub 2006 Oct 27.

PMID:
17110113
11.

Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.

Desroches J, Charron S, Bouchard JF, Beaulieu P.

Neuropharmacology. 2014 Feb;77:441-52. doi: 10.1016/j.neuropharm.2013.10.006. Epub 2013 Oct 19.

PMID:
24148808
12.

The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of Kv7 channels.

Iannotti FA, Silvestri C, Mazzarella E, Martella A, Calvigioni D, Piscitelli F, Ambrosino P, Petrosino S, Czifra G, Bíró T, Harkany T, Taglialatela M, Di Marzo V.

Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):E2472-81. doi: 10.1073/pnas.1406728111. Epub 2014 Jun 3.

13.

Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.

Duncan M, Millns P, Smart D, Wright JE, Kendall DA, Ralevic V.

Br J Pharmacol. 2004 Jun;142(3):509-18. Epub 2004 May 17.

14.

Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol.

Ghafouri N, Tiger G, Razdan RK, Mahadevan A, Pertwee RG, Martin BR, Fowler CJ.

Br J Pharmacol. 2004 Nov;143(6):774-84. Epub 2004 Oct 18.

15.

Why do cannabinoid receptors have more than one endogenous ligand?

Di Marzo V, De Petrocellis L.

Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3216-28. doi: 10.1098/rstb.2011.0382. Review.

16.

The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.

Chicca A, Marazzi J, Gertsch J.

Br J Pharmacol. 2012 Dec;167(8):1596-608. doi: 10.1111/j.1476-5381.2012.02059.x.

17.

Brain regional cannabinoid CB(1) receptor signalling and alternative enzymatic pathways for 2-arachidonoylglycerol generation in brain sections of diacylglycerol lipase deficient mice.

Aaltonen N, Riera Ribas C, Lehtonen M, Savinainen JR, Laitinen JT.

Eur J Pharm Sci. 2014 Jan 23;51:87-95. doi: 10.1016/j.ejps.2013.08.035. Epub 2013 Sep 3.

PMID:
24012970
18.

Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.

Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW.

Mol Pharmacol. 2000 May;57(5):1045-50.

PMID:
10779390
19.

Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.

Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, Shohami E, Spatz M.

Brain Res Mol Brain Res. 2004 Dec 6;132(1):87-92.

PMID:
15548432
20.

Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro.

Whyte LS, Ford L, Ridge SA, Cameron GA, Rogers MJ, Ross RA.

Br J Pharmacol. 2012 Apr;165(8):2584-97. doi: 10.1111/j.1476-5381.2011.01519.x.

Supplemental Content

Support Center